PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 13, 2026Journal of Medicinal Chemistry0 citations

Identification of an Hsp110/HDAC6 Dual-Target Inhibitor for the Effective Treatment of Pulmonary Arterial Hypertension via Synergistic Blockade of Vascular Remodeling

View Full Paper
MLMengqi LiYWYue WangXLXinru Liang

Key Points

  • This research aims to explore a dual-target inhibitor for treating pulmonary arterial hypertension by blocking vascular remodeling.
  • Identified an Hsp110/HDAC6 dual-target inhibitor
  • Assessed its effects on vascular remodeling
  • Analyzed the compounds' potential in pulmonary arterial hypertension.
  • Demonstrated enhanced suppressive effects on vascular remodeling
  • Offered a promising lead compound for PAH treatment

Abstract

demonstrated enhanced suppressive effects on vascular remodeling through synchronous regulation of dual targets. In summary, the present study provides novel research insights into developing novel PAH drugs based on antivascular remodeling strategies and offers a promising lead compound.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/6a03cbe01c527af8f1ecfa74https://doi.org/10.1021/acs.jmedchem.6c00066
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Discovery and Optimization of Hsp110 and sGC Dual-Target Regulators for the Treatment of Pulmonary Arterial Hypertension2024 · 5 citations
  2. 2Therapeutic Targeting of Vascular Remodeling and Right Heart Failure in Pulmonary Arterial Hypertension with a HIF-2α Inhibitor2018 · 168 citations
  3. 3Discovery of Novel Pyrazolo[3,4-<i>b</i>] Pyridine Derivatives with Dual Activities of Vascular Remodeling Inhibition and Vasodilation for the Treatment of Pulmonary Arterial Hypertension2020 · 44 citations
  4. 4Selective Class I Histone Deacetylase Inhibition Suppresses Hypoxia-Induced Cardiopulmonary Remodeling Through an Antiproliferative Mechanism2012 · 176 citations
  5. 5NEW OPPORTUNITIES PATHOGENETIC THERAPY OF PULMONARY ARTERIAL HYPERTENSION2013